January's top stories: Bristol-Myers stops Opdivo trial, Boehringer COPD study

Bristol-Myers Squibb (BMS) stopped its open-label, randomised Phase III trial (CheckMate -017) evaluating Opdivo versus docetaxel, Boehringer started patient enrolment in its Dynagito study to treat COPD, while Medivation and Astellas report positive…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news